{
    "nct_id": "NCT05348356",
    "official_title": "A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors",
    "inclusion_criteria": "* Has histologically confirmed recurrent adult-type granulosa cell tumor of the ovary prior to first dose of study treatment\n* Have documented radiological evidence of relapse after at least one systemic therapy that is not amenable to surgery, or radiation and have measurable disease by RECIST v1.1 criteria\n* Have adequate bone marrow, renal and hepatic function as defined by screening visit laboratory values\n\nKey\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has signs of bowel obstruction requiring parenteral nutrition, malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat\n* Has had a major cardiac or thrombo-embolic event within 6 months of signing informed consent\n* Has abnormal QT interval at Screening, or has congenital or acquired long QT syndrome or a history of additional risk factors for Torsades de Pointes\n* Has current or chronic history of liver disease or known hepatic or biliary abnormalities\n* Has received bevacizumab treatment or other monoclonal antibody therapy with targeted anti-angiogenic activity for OvGCT within 28 days (or 5 half-lives, whichever is shorter) prior to the first dose of study treatment;\n* Has received treatment for OvGCT including but not limited to the following within 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment: hormonal therapy, chemotherapy, immunotherapy, targeted therapy or any investigational treatment",
    "miscellaneous_criteria": "Key"
}